Azitra, Inc. (NYSEAMERICAN:AZTR) Stock Short Interest Drops 48.8%

Azitra, Inc. (NYSEAMERICAN:AZTR) was the recipient of a large decline in short interest in September. As of September 15th, there was short interest totaling 701,345 shares, a decline of 48.8% from the August 31st total of 1,368,917 shares. Based on an average daily volume of 510,506 shares, the days-to-cover ratio is presently 1.4 days. Currently, 1.2% of the company’s stock are short sold.

Azitra Stock Performance

Shares of Azitra stock traded down $0.01 during midday trading on Thursday, hitting $0.13. The company had a trading volume of 1,364,802 shares, compared to its average volume of 8,501,013. The company has a 50 day moving average of $0.15 and a 200 day moving average of $0.19. Azitra has a 52-week low of $0.10 and a 52-week high of $1.09.

Azitra (NYSEAMERICAN:AZTR) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05). On average, equities research analysts predict that Azitra will post -0.25 earnings per share for the current fiscal year.

About Azitra

Azitra, Inc is a clinical-stage biotechnology company focused on developing precision dermatology treatments for inflammatory and other skin conditions. The company uses engineered microbes and its proprietary platform to discover and develop live biotherapeutic products intended to address disease-related changes in the skin microbiome and deliver therapeutic proteins locally.

Azitra’s product pipeline has included ATR-12, an engineered strain of Staphylococcus epidermidis designed to produce filaggrin-1 for the potential treatment of Netherton syndrome, a rare genetic skin disorder.